MA38488A1 - Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate - Google Patents

Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Info

Publication number
MA38488A1
MA38488A1 MA38488A MA38488A MA38488A1 MA 38488 A1 MA38488 A1 MA 38488A1 MA 38488 A MA38488 A MA 38488A MA 38488 A MA38488 A MA 38488A MA 38488 A1 MA38488 A1 MA 38488A1
Authority
MA
Morocco
Prior art keywords
quinuclidin
thiazol
propan
fluorophenyl
forms
Prior art date
Application number
MA38488A
Other languages
English (en)
Inventor
Craig Siegel
Jin Zhao
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50543351&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38488A1 publication Critical patent/MA38488A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouvelles formes de sels de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate utiles en tant qu'un inhibiteur de synthase de glucosylcéramide (gcs) et pour le traitement de maladies métaboliques telles que les maladies lysosomales, soit seul, soit en association avec une thérapie de remplacement enzymatique, et pour le traitement du cancer.
MA38488A 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate MA38488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791706P 2013-03-15 2013-03-15
PCT/US2014/027081 WO2014152215A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Publications (1)

Publication Number Publication Date
MA38488A1 true MA38488A1 (fr) 2017-10-31

Family

ID=50543351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38488A MA38488A1 (fr) 2013-03-15 2014-03-14 Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate

Country Status (34)

Country Link
US (1) US9518049B2 (fr)
EP (1) EP2970250B1 (fr)
JP (1) JP6438455B2 (fr)
KR (1) KR102302064B1 (fr)
CN (1) CN105189490A (fr)
AR (1) AR095435A1 (fr)
AU (1) AU2014240028B2 (fr)
BR (1) BR112015022907B1 (fr)
CA (1) CA2906691A1 (fr)
CL (1) CL2015002701A1 (fr)
DK (1) DK2970250T3 (fr)
EA (1) EA037527B1 (fr)
ES (1) ES2872326T3 (fr)
HK (1) HK1214821A1 (fr)
HR (1) HRP20210692T1 (fr)
HU (1) HUE054349T2 (fr)
IL (1) IL241229B (fr)
JO (1) JO3713B1 (fr)
LT (1) LT2970250T (fr)
MA (1) MA38488A1 (fr)
MX (1) MX370178B (fr)
MY (1) MY181766A (fr)
PH (1) PH12015502021A1 (fr)
PL (1) PL2970250T3 (fr)
PT (1) PT2970250T (fr)
RS (1) RS61852B1 (fr)
SA (1) SA515361078B1 (fr)
SG (1) SG11201507054YA (fr)
SI (1) SI2970250T1 (fr)
TN (1) TN2015000427A1 (fr)
TW (1) TWI713438B (fr)
UY (1) UY35439A (fr)
WO (1) WO2014152215A1 (fr)
ZA (1) ZA201506602B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089067A1 (fr) * 2013-12-11 2015-06-18 Genzyme Corporation Inhibiteurs de la glucosylcéramide synthase
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
EP3920912A1 (fr) 2019-02-04 2021-12-15 Genzyme Corporation Traitement de ciliopathies à l'aide d'inhibiteurs de la glucosylcéramide synthase (gcs)
BR112022014553A2 (pt) * 2020-02-03 2022-09-20 Genzyme Corp Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic
IL300090A (en) * 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT
MX2023001285A (es) 2020-07-30 2023-02-22 Genzyme Corp Metodos para reducir la concentracion de glicoesfingolipidos en el tejido cerebral y metodos de tratamiento de enfermedades neurodegenerativas que implican los mismos.
WO2022215083A1 (fr) * 2021-04-05 2022-10-13 Msn Laboratories Private Limited, R&D Center Formes à l'état solide de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl) carbamate ou de sels et procédé de préparation associé
WO2024116127A1 (fr) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat en combinaison avec un inhibiteur fort ou modéré de cyp3a4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
WO2010091104A1 (fr) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibiteurs de la glucosylcéramide synthase
ES2902229T3 (es) 2009-08-28 2022-03-25 Icahn School Med Mount Sinai Terapia de sustitución de la enzima de escalado de la dosis para el tratamiento de la deficiencia de esfingomielinasa ácida
EP3673906A1 (fr) * 2011-03-18 2020-07-01 Genzyme Corporation Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
ES2872326T3 (es) 2021-11-02
PH12015502021A1 (en) 2016-01-11
BR112015022907A8 (pt) 2019-11-26
EA037527B1 (ru) 2021-04-08
MY181766A (en) 2021-01-06
RS61852B1 (sr) 2021-06-30
HUE054349T2 (hu) 2021-09-28
JP6438455B2 (ja) 2018-12-12
CN105189490A (zh) 2015-12-23
TWI713438B (zh) 2020-12-21
UY35439A (es) 2014-10-31
IL241229A0 (en) 2015-11-30
WO2014152215A1 (fr) 2014-09-25
US20160039805A1 (en) 2016-02-11
EP2970250A1 (fr) 2016-01-20
HRP20210692T1 (hr) 2021-06-11
IL241229B (en) 2019-12-31
SI2970250T1 (sl) 2021-06-30
CL2015002701A1 (es) 2016-03-18
KR102302064B1 (ko) 2021-09-13
ZA201506602B (en) 2023-04-26
TN2015000427A1 (en) 2017-01-03
HK1214821A1 (zh) 2016-08-05
AU2014240028A1 (en) 2015-10-15
NZ712659A (en) 2020-11-27
SA515361078B1 (ar) 2018-06-14
BR112015022907A2 (pt) 2017-07-18
MX2015012295A (es) 2016-05-16
EP2970250B1 (fr) 2021-04-21
BR112015022907B1 (pt) 2022-07-12
AU2014240028B2 (en) 2018-08-02
TW201502127A (zh) 2015-01-16
AR095435A1 (es) 2015-10-14
PL2970250T3 (pl) 2021-12-06
JP2016513679A (ja) 2016-05-16
MX370178B (es) 2019-12-04
DK2970250T3 (da) 2021-07-12
PT2970250T (pt) 2021-05-07
KR20150132333A (ko) 2015-11-25
SG11201507054YA (en) 2015-10-29
CA2906691A1 (fr) 2014-09-25
EA201591706A1 (ru) 2016-02-29
JO3713B1 (ar) 2021-01-31
LT2970250T (lt) 2021-05-10
US9518049B2 (en) 2016-12-13

Similar Documents

Publication Publication Date Title
MA38488A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
MA37975B2 (fr) Inhibiteurs de synthase de glucosylcéramide
PH12016502167A1 (en) Hdl theraphy markers
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2015003731A1 (es) Inhibidores de bromodominios
EA201692050A1 (ru) Лечение неалкогольной жировой болезни печени и неалкогольного стеатогепатита
EA201890641A2 (ru) СТИМУЛЯТОРЫ sGC
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
EA201791993A1 (ru) Способы лечения протеинопатий
PH12018501443A1 (en) Methods of administering hepcidin
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2018002263A (es) Potenciador de atp intracelular.
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
MX2019005627A (es) Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.
MX2019014306A (es) Agente para reducir la cantidad de proteina beta amiloide.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
PH12019501358A1 (en) Methods of administering hepcidin
MA44634A1 (fr) Formes de sel de (s)-quinuclidin-3-yl (2-(2-(4-fluorophényl)thiazol-4-yl)propan-2-yl)carbamate
NZ723206A (en) A method of improving liver function
MX2017000184A (es) Agentes de interaccion enzimatica.